These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 318766)

  • 21. [Biologically active hydroxamic acids--iron complexons].
    Kol'tsova GN; Mel'nikovskaia NN; Likhodzievskiĭ KG; Rozenberg GIa
    Gematol Transfuziol; 1984 Sep; 29(9):56-9. PubMed ID: 6394425
    [No Abstract]   [Full Text] [Related]  

  • 22. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iron absorption in non-transfused iron loading anaemias: prediction of risk for iron loading, and response to iron chelation treatment, in beta thalassaemia intermedia and congenital sideroblastic anaemias.
    Pippard MJ; Weatherall DJ
    Haematologia (Budap); 1984; 17(1):17-24. PubMed ID: 6724353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The development of new drugs for use in iron chelation therapy.
    Grady RW
    Birth Defects Orig Artic Ser; 1976; 12(8):161-75. PubMed ID: 795480
    [No Abstract]   [Full Text] [Related]  

  • 25. Desferrioxamine: its use in iron chelation in thalassemia.
    Sharma BK; Choudhury P; Dubey AP
    Indian Pediatr; 1990 Mar; 27(3):314-9. PubMed ID: 2190932
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical Management of Patients With Thalassemia Syndromes.
    Martin M; Haines D
    Clin J Oncol Nurs; 2016 Jun; 20(3):310-7. PubMed ID: 27206298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defective vitamin D metabolism in thalassemia major.
    Zaino EC; Yeh JK; Aloia J
    Ann N Y Acad Sci; 1985; 445():127-34. PubMed ID: 3874574
    [No Abstract]   [Full Text] [Related]  

  • 29. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iron chelation in thalassemia.
    Pippard MJ
    Birth Defects Orig Artic Ser; 1988; 23(5B):35-40. PubMed ID: 3390560
    [No Abstract]   [Full Text] [Related]  

  • 31. Early iron chelation therapy in thalassemia major.
    Russo G; Romeo MA; Musumeci S; Schilirò G; Di Gregorio F
    Haematologica; 1983; 68(1):69-73. PubMed ID: 6404710
    [No Abstract]   [Full Text] [Related]  

  • 32. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
    Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
    [No Abstract]   [Full Text] [Related]  

  • 35. Quality of life in thalassemia.
    Telfer P; Constantinidou G; Andreou P; Christou S; Modell B; Angastiniotis M
    Ann N Y Acad Sci; 2005; 1054():273-82. PubMed ID: 16339675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register.
    Modell B; Khan M; Darlison M
    Lancet; 2000 Jun; 355(9220):2051-2. PubMed ID: 10885361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose chelation therapy in thalassaemia.
    Lancet; 1984 Feb; 1(8373):373-4. PubMed ID: 6141429
    [No Abstract]   [Full Text] [Related]  

  • 38. Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):287-95. PubMed ID: 19814674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DESFERRIOXAMINE IN HB-E-THALASSAEMIA DISEASE.
    RAY RN; CHATTERJEA JB; GHOSH SK
    Bull Calcutta Sch Trop Med; 1963 Jul; 11():113-4. PubMed ID: 14068662
    [No Abstract]   [Full Text] [Related]  

  • 40. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.